Keyword: Trans-Pacific Partnership
Biopharma shares soared with Donald Trump's presidential victory as the threat of sweeping action against drug prices lifted. But Trump won't be idle on pricing, analysts say, and his ferocious opposition to trade deals could be a long-term headache for the decidedly global pharma business.
Novartis agreed to work with Colombia to lower the price of its cancer drug Gleevec, to prevent the country from issuing a compulsory license for the med. But the clock is ticking, Colombian health officials said.
Two leaked letters written by a representative of the Embassy of Colombia in Washington, DC, and sent to officials in that country showcase deep tensions over a plan by the government there to issue a compulsory license and allow generics of Novartis’ cancer med Gleevec.